10:12 AM EDT, 06/26/2025 (MT Newswires) -- 3D Systems ( DDD ) said Thursday its 3D bioprinting technology helped win US Food and Drug Administration approval for its partner Tissium's bioabsorbable 3D-printed medical device for the regenerative repair of damaged peripheral nerves.

The company said it collaborated with Tissium to develop the Coaptium Connect with Tissium Light, a sutureless and atraumatic device for peripheral nerve repair.

Earlier this week, Tissium announced that the FDA had granted de novo marketing authorization for the device, 3D Systems ( DDD ) said.

Shares of 3D Systems ( DDD ) were up more than 5% in recent trading Thursday.

Price: 1.47, Change: +0.08, Percent Change: +5.54